NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD
Overall CERS gets a fundamental rating of 2 out of 10. We evaluated CERS against 188 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CERS is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.16% | ||
ROE | -34.14% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 60.6% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.17 | ||
Debt/FCF | 12.67 | ||
Altman-Z | -4.78 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.32 | ||
Quick Ratio | 1.63 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 41.9 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.47
-0.04 (-2.65%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.36 | ||
P/FCF | 41.9 | ||
P/OCF | 32.84 | ||
P/B | 5.06 | ||
P/tB | 5.19 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.16% | ||
ROE | -34.14% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 60.6% | ||
FCFM | 3.24% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.17 | ||
Debt/FCF | 12.67 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 120.84% | ||
Cap/Sales | 0.89% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.32 | ||
Quick Ratio | 1.63 | ||
Altman-Z | -4.78 |